Genetic basis of familial dyslipidemia and hypertension: 15-year results from Utah.
The genetic and environmental determinants of hypertension, lipid abnormalities, and coronary artery disease (CAD) have been studied for 15 years in Utah in population-based multigenerational pedigrees (2500 subjects among 98 pedigrees), twin pairs (74 monozygous and 78 dizygous), hypertensive siblings (131 sibships), siblings with CAD before age 55 (45 sibships), and anecdotally ascertained pedigrees with type II diabetes (271 subjects among 16 pedigrees), lipoprotein lipase deficiency (106 subjects in a single pedigree), and familial hypercholesterolemia (502 heterozygotes among 50 pedigrees). Estimates of heritability ranged from 20 to 75% for blood pressures and blood lipids. A strong positive family history predicts a future occurrence of hypertension (relative risk [RR] = 3.8) and CAD (RR = 12.7). Segregating single-gene effects were found for several 'intermediate phenotypes' associated with hypertension (erythrocyte sodium-lithium countertransport, intraerythrocytic sodium, a relative fat pattern, total urinary kallikrein excretion, and fasting insulin levels). Strong single-gene effects in segregation analysis were also found for low-density lipoprotein (LDL) cholesterol, lipoprotein (a) (Lp[a]), low high-density lipoprotein (HDL) cholesterol, and high apolipoprotein (apo) B. Deoxyribonucleic acid (DNA) markers of lipid abnormalities or hypertension have included LDL-receptor defects, lipoprotein lipase deficiency, high Lp(a), familial defective apo B, decreased quantitative levels of apo B, apo E phenotype, angiotensinogen, and 'glucocorticoid remediable aldosteronism (GRA) hypertension.' Also tested in Utah studies, but not found to be DNA markers for hypertension, were the genetic loci for the structural genes for renin and angiotensin-converting enzyme, and the sodium antiport system. In addition, important gene-gene interactions (LDL receptor with apo E2) and gene-environment interactions (kallikrein with potassium intake) were found.(ABSTRACT TRUNCATED AT 250 WORDS)
Williams
R R
RR
Department of Internal Medicine, University of Utah Cardiovascular Genetics Research Clinic, Salt Lake City 84108.
Hunt
S C
SC
Hopkins
P N
PN
Wu
L L
LL
Hasstedt
S J
SJ
Berry
T D
TD
Barlow
G K
GK
Stults
B M
BM
Schumacher
M C
MC
Ludwig
E H
EH
D000375:Aging / Q000235:genetics; D001055:Apolipoproteins B / Q000032:analysis; D001057:Apolipoproteins E / Q000032:analysis; D001794:Blood Pressure / Q000502:physiology; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D004247:DNA / Q000032:analysis / Q000235:genetics; D004200:Diseases in Twins / Q000453:epidemiology / Q000235:genetics; D004777:Environment; D005192:Family Health; D005796:Genes / Q000235:genetics; D006801:Humans; D006950:Hyperlipidemia, Familial Combined / Q000150:complications / Q000453:epidemiology / Q000235:genetics*; D006973:Hypertension / Q000150:complications / Q000453:epidemiology / Q000235:genetics*; D015994:Incidence; D007328:Insulin / Q000097:blood; D007610:Kallikreins / Q000652:urine; D008055:Lipids / Q000097:blood; D017270:Lipoprotein(a) / Q000097:blood; D010375:Pedigree; D007703:Peptidyl-Dipeptidase A / Q000235:genetics; D010641:Phenotype; D012083:Renin / Q000235:genetics; D012307:Risk Factors; D014589:Utah / Q000453:epidemiology
D001055:Apolipoproteins B; D001057:Apolipoproteins E; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D007328:Insulin; D008055:Lipids; D017270:Lipoprotein(a); D004247:DNA; D007703:Peptidyl-Dipeptidase A; D007610:Kallikreins; D012083:Renin